Hospital
Bozeman Health Deaconess Hospital
Bozeman Health Deaconess Hospital was paid $4.47M by Medicaid between Jan 2018 and Dec 2024, across 334 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.
33Billing provider infoBOZEMAN HEALTH DEACONESS HOSPITAL
BOZEMAN, MT 59715
BOZEMAN, MT 59715
33aNPI1104295864assigned 09/23/2015
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$4.47M
24GClaims870,767
24DCodes billed334
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in Montana
Rank by total paid#1 of 8
Median peer was paid$14K
This provider vs. median308×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 136,117 | $642K | |
| 2019 | 125,528 | $678K | |
| 2020 | 115,098 | $614K | |
| 2021 | 142,014 | $728K | |
| 2022 | 131,800 | $802K | |
| 2023 | 134,819 | $558K | |
| 2024incomplete | 85,391 | $445K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 22,464 | 18,087 | $636K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 12,001 | 10,548 | $417K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 8.0% | 13,932 | 5,063 | $359K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 10,303 | 9,251 | $306K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6.0% | 11,046 | 3,124 | $267K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 3,592 | 3,249 | $172K |
| G0378 | Hospital observation service, per hour | 3.5% | 4,573 | 2,447 | $156K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 3,590 | 3,068 | $116K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 9,517 | 8,874 | $111K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.4% | 6,898 | 6,309 | $108K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 628 | 604 | $78K |
| 93975 | 1.7% | 1,164 | 1,063 | $75K |
322 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 17,676 | $63K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 4,023 | $61K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.1% | 508 | $51K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 13,024 | $48K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 199 | $43K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,483 | $41K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,757 | $38K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,578 | $38K |
| 87631 | <1% | 587 | $36K | |
| 80053 | Comprehensive metabolic panel | <1% | 48,058 | $35K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,656 | $34K |
| 80050 | General health panel | <1% | 12,169 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,024 | $32K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,738 | $31K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 81 | $31K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,984 | $28K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,223 | $27K |
| 74018 | <1% | 1,620 | $26K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,711 | $26K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,862 | $25K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 958 | $25K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,544 | $25K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,680 | $25K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,471 | $23K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,415 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,208 | $21K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 143 | $20K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,347 | $19K |
| J3490 | Unclassified drugs | <1% | 2,342 | $18K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,180 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,043 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,995 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,704 | $16K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 657 | $16K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,992 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 623 | $14K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,313 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,734 | $13K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 406 | $13K |
| 82728 | <1% | 5,101 | $12K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,719 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,131 | $11K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 907 | $11K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 365 | $11K |
| 96376 | <1% | 4,109 | $11K | |
| 87081 | <1% | 3,816 | $11K | |
| 97161 | <1% | 2,451 | $11K | |
| 73110 | <1% | 890 | $11K | |
| 80061 | Lipid panel | <1% | 14,432 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,809 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,921 | $10K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,531 | $10K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,155 | $9K |
| 73610 | <1% | 1,239 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,089 | $9K |
| 83516 | <1% | 1,636 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,299 | $9K |
| 84703 | <1% | 7,931 | $9K | |
| 86140 | <1% | 11,431 | $9K | |
| 97162 | <1% | 1,580 | $8K | |
| 83690 | <1% | 8,247 | $8K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,285 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,380 | $7K |
| 84439 | <1% | 4,878 | $7K | |
| 73630 | <1% | 1,438 | $7K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 141 | $7K |
| 85027 | <1% | 8,539 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 772 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 572 | $7K |
| 82784 | <1% | 1,933 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,655 | $7K |
| 83605 | <1% | 2,732 | $6K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,560 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,607 | $6K |
| 87077 | <1% | 5,527 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 398 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,303 | $6K |
| 81001 | <1% | 11,011 | $6K | |
| 87040 | <1% | 972 | $5K | |
| 86003 | <1% | 185 | $5K | |
| 87480 | <1% | 5,343 | $5K | |
| 87510 | <1% | 5,342 | $5K | |
| 87660 | <1% | 5,344 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,785 | $5K |
| 81025 | <1% | 4,165 | $4K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,667 | $4K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 965 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,157 | $4K |
| 73130 | <1% | 744 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,736 | $4K |
| 76770 | <1% | 213 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,021 | $4K |
| 87070 | <1% | 3,086 | $4K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 29 | $4K |
| 84145 | <1% | 1,266 | $4K | |
| 87186 | <1% | 3,940 | $4K | |
| 73562 | <1% | 707 | $4K | |
| 93971 | <1% | 1,137 | $3K | |
| 83550 | <1% | 3,232 | $3K | |
| 86900 | <1% | 4,818 | $3K | |
| 88304 | <1% | 328 | $3K | |
| 81003 | <1% | 6,724 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,907 | $3K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,789 | $3K |
| 73140 | <1% | 174 | $3K | |
| 82077 | <1% | 3,443 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 842 | $3K |
| 80143 | <1% | 1,610 | $3K | |
| 85379 | <1% | 2,758 | $3K | |
| 88342 | <1% | 555 | $3K | |
| 85652 | <1% | 5,952 | $2K | |
| 73030 | <1% | 832 | $2K | |
| 80179 | <1% | 1,509 | $2K | |
| 84484 | <1% | 4,782 | $2K | |
| 87486 | <1% | 408 | $2K | |
| 87581 | <1% | 408 | $2K | |
| 83735 | <1% | 3,363 | $2K | |
| 83880 | <1% | 2,384 | $2K | |
| 82803 | <1% | 123 | $2K | |
| 86850 | <1% | 4,667 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,472 | $2K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 258 | $2K |
| 99152 | <1% | 604 | $2K | |
| 94762 | <1% | 233 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,992 | $2K |
| 82948 | <1% | 3,371 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 26,733 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,369 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,837 | $2K |
| 72100 | <1% | 730 | $2K | |
| 83540 | <1% | 2,247 | $2K | |
| 84403 | <1% | 932 | $2K | |
| 84481 | <1% | 1,806 | $2K | |
| 82607 | <1% | 2,563 | $2K | |
| 76937 | <1% | 1,677 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 371 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 96 | $2K |
| 85610 | <1% | 9,133 | $2K | |
| 29125 | <1% | 157 | $2K | |
| 84702 | <1% | 2,644 | $2K | |
| 73080 | <1% | 80 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,522 | $2K |
| 86376 | <1% | 1,234 | $1K | |
| 70486 | <1% | 35 | $1K | |
| 90839 | <1% | 55 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 213 | $1K |
| 86901 | <1% | 4,809 | $1K | |
| 97165 | <1% | 89 | $1K | |
| 87205 | <1% | 2,535 | $1K | |
| 84100 | <1% | 1,786 | $1K | |
| 73502 | <1% | 272 | $1K | |
| 86038 | <1% | 1,190 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,028 | $1K |
| 80076 | <1% | 757 | $1K | |
| 92523 | <1% | 25 | $984.99 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 184 | $966.32 |
| 87147 | <1% | 387 | $948.81 | |
| 86780 | <1% | 3,187 | $918.94 | |
| 97597 | <1% | 1,205 | $901.16 | |
| 85730 | <1% | 846 | $850.89 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 38 | $830.66 |
| 84146 | <1% | 402 | $826.75 | |
| 0352U | <1% | 205 | $825.63 | |
| 94729 | <1% | 314 | $763.23 | |
| 86364 | <1% | 197 | $739.86 | |
| C1769 | Guide wire | <1% | 564 | $735.09 |
| 83615 | <1% | 1,298 | $716.18 | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 29 | $663.99 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,477 | $658.76 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 581 | $637.24 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 74 | $602.68 |
| 84550 | <1% | 1,087 | $588.29 | |
| 86803 | <1% | 4,111 | $576.78 | |
| 82670 | <1% | 311 | $560.08 | |
| 97035 | <1% | 2,725 | $543.17 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,738 | $539.31 |
| 12011 | <1% | 13 | $532.29 | |
| 83970 | <1% | 283 | $507.65 | |
| 86308 | <1% | 214 | $474.31 | |
| 82570 | <1% | 2,785 | $458.18 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 57 | $450.00 |
| 82550 | <1% | 847 | $448.38 | |
| 94726 | <1% | 259 | $442.90 | |
| 96367 | <1% | 935 | $441.75 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 231 | $441.26 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 2,146 | $417.36 |
| 86431 | <1% | 893 | $408.58 | |
| 73590 | <1% | 44 | $407.34 | |
| 76801 | <1% | 84 | $407.15 | |
| 97116 | <1% | 124 | $393.96 | |
| 87507 | <1% | 56 | $370.47 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 797 | $361.09 |
| 73090 | <1% | 13 | $342.24 | |
| 87075 | <1% | 529 | $340.31 | |
| 90715 | <1% | 258 | $337.22 | |
| 51798 | <1% | 32 | $303.45 | |
| 82043 | <1% | 2,502 | $277.01 | |
| 83001 | <1% | 233 | $276.38 | |
| 94799 | <1% | 30 | $261.79 | |
| 83630 | <1% | 135 | $259.59 | |
| 87046 | <1% | 39 | $244.17 | |
| 93325 | <1% | 50 | $239.35 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,006 | $239.12 |
| 86762 | <1% | 1,146 | $235.64 | |
| 87340 | <1% | 1,810 | $229.44 | |
| 82247 | <1% | 169 | $221.98 | |
| 76536 | <1% | 51 | $207.43 | |
| 87338 | <1% | 25 | $198.10 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 235 | $193.11 |
| 82785 | <1% | 20 | $192.00 | |
| 85007 | <1% | 460 | $188.22 | |
| 80178 | <1% | 527 | $182.31 | |
| 82746 | <1% | 352 | $180.80 | |
| 82375 | <1% | 420 | $178.79 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 145 | $173.04 |
| 86769 | <1% | 96 | $168.52 | |
| 85018 | <1% | 590 | $168.49 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 84 | $160.63 |
| 92567 | <1% | 58 | $159.80 | |
| 80305 | <1% | 274 | $159.13 | |
| 93320 | <1% | 33 | $155.98 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,340 | $146.92 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $142.80 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 112 | $142.66 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 175 | $138.55 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 611 | $132.75 |
| 86480 | <1% | 33 | $120.48 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 414 | $118.22 |
| 87427 | <1% | 27 | $108.36 | |
| 82533 | <1% | 120 | $105.38 | |
| 87045 | <1% | 54 | $103.76 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 356 | $99.72 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,881 | $97.38 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $87.71 |
| 84156 | <1% | 832 | $87.19 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 184 | $76.50 |
| 83721 | <1% | 275 | $69.08 | |
| 36410 | <1% | 925 | $67.13 | |
| 72040 | <1% | 27 | $62.99 | |
| 82274 | <1% | 15 | $61.91 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 229 | $60.97 |
| 87467 | <1% | 578 | $60.14 | |
| 82977 | <1% | 45 | $51.12 | |
| 86255 | <1% | 63 | $46.86 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 144 | $46.13 |
| 90686 | <1% | 387 | $43.12 | |
| 86706 | <1% | 375 | $41.77 | |
| 82950 | <1% | 661 | $36.72 | |
| 83002 | <1% | 15 | $36.00 | |
| 94760 | <1% | 26 | $30.60 | |
| A9270 | Non-covered item or service | <1% | 10,036 | $29.28 |
| 86141 | <1% | 59 | $25.17 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 47 | $23.80 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 194 | $22.95 |
| 80069 | <1% | 15 | $22.38 | |
| 82565 | <1% | 170 | $13.21 | |
| 82248 | <1% | 46 | $13.02 | |
| 86705 | <1% | 243 | $10.37 | |
| 82947 | <1% | 16 | $10.12 | |
| 86709 | <1% | 149 | $9.91 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 67 | $5.66 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $5.60 |
| 83050 | <1% | 162 | $2.93 | |
| 96118 | 0% | 60 | $0.00 | |
| 92557 | 0% | 40 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 44 | $0.00 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 0% | 60 | $0.00 |
| 86200 | 0% | 111 | $0.00 | |
| 84155 | 0% | 30 | $0.00 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 0% | 781 | $0.00 |
| 77336 | 0% | 32 | $0.00 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 0% | 54 | $0.00 |
| 76376 | 0% | 54 | $0.00 | |
| 0097U | 0% | 14 | $0.00 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 117 | $0.00 |
| 11719 | 0% | 13 | $0.00 | |
| 87641 | 0% | 192 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 225 | $0.00 |
| 90653 | 0% | 109 | $0.00 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 0% | 96 | $0.00 |
| 93296 | 0% | 16 | $0.00 | |
| 84165 | 0% | 31 | $0.00 | |
| 94060 | 0% | 44 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 14 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 51 | $0.00 |
| 17110 | 0% | 17 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 20 | $0.00 |
| 80074 | 0% | 105 | $0.00 | |
| 80164 | 0% | 15 | $0.00 | |
| 89051 | 0% | 15 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 238 | $0.00 |
| 87076 | 0% | 16 | $0.00 | |
| 81002 | 0% | 38 | $0.00 | |
| S9443 | Lactation classes, non-physician provider, per session | 0% | 36 | $0.00 |
| 90837 | Psychotherapy session, about an hour | 0% | 27 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 145 | $0.00 |
| 36591 | 0% | 300 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 74 | $0.00 |
| 84153 | 0% | 1,200 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 34 | $0.00 |
| 96415 | 0% | 207 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 491 | $0.00 |
| 90694 | 0% | 75 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 297 | $0.00 |
| 88307 | 0% | 146 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 16 | $0.00 |
| 84144 | 0% | 247 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 35 | $0.00 |
| 94010 | 0% | 12 | $0.00 | |
| 96161 | 0% | 60 | $0.00 | |
| 96119 | 0% | 38 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 12 | $0.00 |
| 76870 | 0% | 14 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 23 | $0.00 |
| 96127 | 0% | 59 | $0.00 | |
| 96120 | 0% | 36 | $0.00 | |
| 84402 | 0% | 15 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 49 | $0.00 |
| 12002 | 0% | 15 | $0.00 | |
| 58300 | 0% | 14 | $0.00 | |
| 70496 | 0% | 15 | $0.00 | |
| 12001 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLIBERTINI, ANGIE (PAYER ENROLLMENT SUPERVISOR)
| Provider | Location | Paid |
|---|---|---|
| Bozeman Health Urgent Care | Bozeman, MT | $1.39M |
| Bozeman Health Big Sky Medical Center, LLC | Big Sky, MT | $17K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.